ATE240732T1 - Ziprasidonhaltige arzneimittel - Google Patents

Ziprasidonhaltige arzneimittel

Info

Publication number
ATE240732T1
ATE240732T1 AT99304451T AT99304451T ATE240732T1 AT E240732 T1 ATE240732 T1 AT E240732T1 AT 99304451 T AT99304451 T AT 99304451T AT 99304451 T AT99304451 T AT 99304451T AT E240732 T1 ATE240732 T1 AT E240732T1
Authority
AT
Austria
Prior art keywords
products containing
medicinal products
containing ziprasidone
ziprasidone
medicinal
Prior art date
Application number
AT99304451T
Other languages
English (en)
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE240732(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE240732T1 publication Critical patent/ATE240732T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT99304451T 1998-06-15 1999-06-08 Ziprasidonhaltige arzneimittel ATE240732T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (1)

Publication Number Publication Date
ATE240732T1 true ATE240732T1 (de) 2003-06-15

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99304451T ATE240732T1 (de) 1998-06-15 1999-06-08 Ziprasidonhaltige arzneimittel

Country Status (44)

Country Link
US (1) US6150366A (de)
EP (1) EP0965343B1 (de)
JP (2) JP3441676B2 (de)
KR (1) KR100338915B1 (de)
CN (1) CN1307994C (de)
AP (1) AP1216A (de)
AR (1) AR015553A1 (de)
AT (1) ATE240732T1 (de)
AU (1) AU753820B2 (de)
BG (1) BG64691B1 (de)
BR (1) BR9902268A (de)
CA (1) CA2274338C (de)
CO (1) CO5070579A1 (de)
CY (1) CY2003002I1 (de)
CZ (1) CZ297954B6 (de)
DE (1) DE69908021T2 (de)
DK (1) DK0965343T3 (de)
EA (1) EA002223B1 (de)
ES (1) ES2197581T3 (de)
GT (1) GT199900080A (de)
HN (1) HN1999000089A (de)
HR (1) HRP990193B1 (de)
HU (1) HU226487B1 (de)
ID (1) ID23546A (de)
IL (1) IL130424A (de)
IS (1) IS2182B (de)
MA (1) MA26647A1 (de)
MY (1) MY121397A (de)
NO (1) NO316713B1 (de)
NZ (1) NZ336271A (de)
OA (1) OA11064A (de)
PA (1) PA8475601A1 (de)
PE (1) PE20000632A1 (de)
PL (2) PL195209B1 (de)
PT (1) PT965343E (de)
RS (1) RS49611B (de)
SG (1) SG77243A1 (de)
SI (1) SI0965343T1 (de)
SK (1) SK286245B6 (de)
TR (1) TR199901379A2 (de)
TW (1) TW590774B (de)
UA (1) UA59383C2 (de)
UY (1) UY25649A1 (de)
ZA (1) ZA993938B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
OA11946A (en) * 1999-05-27 2006-04-13 Pfizer Prod Inc Ziprasidone suspension.
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． 制御放出ヒドロコドン処方
CN101653411A (zh) 2000-10-30 2010-02-24 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
JP4545584B2 (ja) 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1546146A1 (de) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited Polymorphe formen von zipradison hcl und ihr verfahren zur herstellung
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
AU2003285600A1 (en) * 2003-11-28 2005-06-24 Siddiqui Mohammed Jaweed Mukarram Process for the preparing ziprasidone monohydrochloride hydrate
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
EP1703898A2 (de) * 2003-12-31 2006-09-27 Alpharma, Inc. Formulierungen enthaltend ziprasidon
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
DE602005018171D1 (de) * 2004-02-27 2010-01-21 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
EP1744750A2 (de) * 2004-05-06 2007-01-24 Sandoz AG Pharmazeutische zusammensetzung mit wasserabweisendem wirkstoff mit erhöhter löslichkeit
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
KR20070046892A (ko) 2004-08-31 2007-05-03 화이자 프로덕츠 인크. 저용해도 약물 및 중합체를 포함하는 제약 투여형
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (de) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Wasserfreies ziprasidon-mesylat und verfahren zu seiner herstellung
EP1874268A1 (de) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injizierbare depot-formulierungen und verfahren zur verzögerten freisetzung von nanoteilchenförmigen zusammensetzungen
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2605447A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
JP4733120B2 (ja) 2005-05-26 2011-07-27 大日本住友製薬株式会社 医薬品組成物
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1889844A3 (de) * 2006-08-02 2008-03-05 Krka Polymorphe Formen von Ziprasidonsulfaten
EP1892243A1 (de) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphe Formen von Ziprasidon Sulfat Salzen
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
WO2009116085A2 (en) * 2008-03-11 2009-09-24 Alkem Laboratories Ltd. An improved process for the preparation of ziprasidone
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
EP2340834A1 (de) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Erhöhte Löslichkeit von Ziprasidon
EP3659604A1 (de) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
DK3246021T3 (da) 2010-02-25 2020-02-03 Bristol Myers Squibb Holdings Ireland Apixabanformuleringer
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DE69726206T2 (de) * 1996-02-13 2004-04-15 Pfizer Inc. Prodrogen von 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit

Also Published As

Publication number Publication date
CN1307994C (zh) 2007-04-04
BG103489A (en) 2000-07-31
IL130424A0 (en) 2000-06-01
KR100338915B1 (ko) 2002-05-30
IS2182B (is) 2006-12-15
NZ336271A (en) 2000-10-27
JP2002003492A (ja) 2002-01-09
JP3441676B2 (ja) 2003-09-02
JP2000007566A (ja) 2000-01-11
MA26647A1 (fr) 2004-12-20
NO316713B1 (no) 2004-04-13
NO992892D0 (no) 1999-06-14
UA59383C2 (uk) 2003-09-15
EP0965343A2 (de) 1999-12-22
IS5079A (is) 1999-12-16
KR20000006143A (ko) 2000-01-25
CZ297954B6 (cs) 2007-05-09
IL130424A (en) 2003-10-31
HK1024184A1 (en) 2000-10-05
AU3398399A (en) 1999-12-23
DE69908021D1 (de) 2003-06-26
HU226487B1 (en) 2009-03-02
MY121397A (en) 2006-01-28
PL333737A1 (en) 1999-12-20
TW590774B (en) 2004-06-11
SK286245B6 (sk) 2008-06-06
GT199900080A (es) 2000-11-29
SK76999A3 (en) 2000-12-11
CN1242987A (zh) 2000-02-02
HN1999000089A (es) 1999-11-03
HU9901960D0 (en) 1999-08-30
HRP990193B1 (en) 2003-08-31
DK0965343T3 (da) 2003-08-04
US6150366A (en) 2000-11-21
HUP9901960A3 (en) 2000-09-28
ZA993938B (en) 2000-12-14
SG77243A1 (en) 2000-12-19
TR199901379A2 (xx) 2000-01-21
AP9901579A0 (en) 1999-06-30
EA002223B1 (ru) 2002-02-28
EP0965343B1 (de) 2003-05-21
AR015553A1 (es) 2001-05-02
CZ212799A3 (cs) 2000-09-13
RS49611B (sr) 2007-06-04
UY25649A1 (es) 2000-02-23
BG64691B1 (bg) 2005-12-30
HRP990193A2 (en) 2000-02-29
NO992892L (no) 1999-12-16
AU753820B2 (en) 2002-10-31
CA2274338C (en) 2003-04-15
PT965343E (pt) 2003-08-29
ID23546A (id) 2000-05-04
BR9902268A (pt) 2000-05-02
ES2197581T3 (es) 2004-01-01
CA2274338A1 (en) 1999-12-15
OA11064A (en) 2002-03-13
DE69908021T2 (de) 2003-11-27
YU27199A (sh) 2002-12-10
AP1216A (en) 2003-10-19
PA8475601A1 (es) 2000-09-29
CY2003002I1 (el) 2009-11-04
PL195209B1 (pl) 2007-08-31
EA199900467A3 (ru) 2000-04-24
PL195606B1 (pl) 2007-10-31
HUP9901960A2 (hu) 2000-08-28
JP4187423B2 (ja) 2008-11-26
EP0965343A3 (de) 2000-02-23
PE20000632A1 (es) 2000-07-26
SI0965343T1 (en) 2003-10-31
EA199900467A2 (ru) 1999-12-29
CO5070579A1 (es) 2001-08-28

Similar Documents

Publication Publication Date Title
ATE240732T1 (de) Ziprasidonhaltige arzneimittel
ATE202472T1 (de) Arzneimittel enthaltend oxaliplatin
ATE285774T1 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
ATE318137T1 (de) Parenteral anzuwendendes bisphosphonathaltiges arzneimittel
ATE187063T1 (de) Arzneimittel
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
NO20004391D0 (no) Duftforsterkende preparater for kosmetikkprodukter
ATE380814T1 (de) Kinaseinhibitoren als arzneimittel
ATE248594T1 (de) Irbesartanhaltiges arzneimittel
IL141456A0 (en) Rhodanine derivatives and pharmaceutical compositions containing the same
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
ATE367150T1 (de) Arzneimittel
DE59712694D1 (de) Stabilisiertes arzneimittel enthaltend cysteinylderivate
EP1049474A4 (de) Cannabimimetische lipidamide als arzneimittel
ATE237320T1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
ID27150A (id) Sediaan levotiroksin bahan farmasi
ATE298576T1 (de) Arzneizubereitungen
DE69709349D1 (de) Arzneimittel bestehend aus diclofenac
ATE359085T1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
IT1302969B1 (it) Confezione per sostanze medicinali
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
DE60008237D1 (de) Lamivudin enthaltende arzneimittel
ATE237309T1 (de) Arzneizubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0965343

Country of ref document: EP